BiotechTube

Fostamatinib Disodium

Phase 3Completed
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Thrombocytopenic Purpura

Conditions

Immune Thrombocytopenic Purpura

Trial Timeline

Oct 1, 2014 → Jun 2, 2020

NCT ID
NCT02077192

About Fostamatinib Disodium

Fostamatinib Disodium is a phase 3 stage product being developed by Rigel Pharmaceuticals for Immune Thrombocytopenic Purpura. The current trial status is completed. This product is registered under clinical trial identifier NCT02077192. Target conditions include Immune Thrombocytopenic Purpura.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT04138927Phase 3Recruiting
NCT02077192Phase 3Completed
NCT00798096Phase 2Completed

Competing Products

20 competing products in Immune Thrombocytopenic Purpura

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
41
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
44
SatralizumabChugai PharmaceuticalPhase 3
77
Placebo + LusutrombopagShionogiPhase 2
52
LusutrombopagShionogiPhase 2
52
RomiplostimKyowa KirinPhase 1/2
41
AMG 531Kyowa KirinPhase 2/3
65
Romiplostim + PlaceboKyowa KirinPhase 3
77
Romiplostim (AMG-531)Kyowa KirinPhase 2
52
Romiplostim and danazolKyowa KirinPhase 2
52
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
33
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
77
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
HerombopagJiangsu Hengrui MedicinePhase 3
77
Zostavax®MerckPre-clinical
23
Raltegravir + AtazanavirMerckPre-clinical
23
ZostavaxMerckPre-clinical
23
MK-8723 + Matching PlaceboMerckPhase 1
33

Other Products from Rigel Pharmaceuticals

Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesApproved
77
Fostamatinib Disodium + PlaceboPhase 3
69
Fostamatinib disodiumPhase 3
69
Fostamatinib + PlaceboPhase 3
69
Fostamatinib disodium + PlaceboPhase 3
69